Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

Kyongbo Pharmaceutical Revenue

Kyongbo Pharmaceutical had revenue of 75.22B KRW in the quarter ending June 30, 2026, with 15.17% growth. This brings the company's total for the last twelve months to 279.55B, up 14.83% year-over-year. In the year 2025, Kyongbo Pharmaceutical had annual revenue of 264.10B with 10.71% growth. That makes Kyongbo Pharmaceutical the 17,058th largest company in the world by revenue and 857th in South Korea.

• Revenue (ttm): 279.55B
• Revenue Growth: +14.83%
• P/S Ratio: 0.44
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 122.64B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Raw Material 138.27B 58.0%
• Finished Products 100.29B 42.0%

By Geography

• South Korea 199.83B 83.8%
• Asia 35.60B 14.9%
• Europe 2.98B 1.2%
• Other 151.41M 0.1%

Fiscal year ended Dec 31, 2024 See the full Kyongbo Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	264.10B	25.55B	10.71%
Dec 31, 2024	238.56B	22.20B	10.26%
Dec 31, 2023	216.36B	20.09B	10.24%
Dec 31, 2022	196.26B	25.61B	15.00%
Dec 31, 2021	170.66B	-44.63B	-20.73%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error